Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Revenues	[1]	$ 30,373	$ 25,973
Cost of products sold		23,415	18,995
Gross profit		6,958	6,978
Operating expenses:
Research and development		1,857	1,647
Selling, general and administrative		5,396	4,379
Total operating expenses		7,253	6,026
Operating (loss) income		(295)	952
Other (expense) income:
Interest and financing expense		(134)	(56)
Miscellaneous income		17	0
Total other expense		(117)	(56)
(Loss) income before income taxes		(412)	896
Income tax (benefit) provision		(251)	217
Net (loss) income		(161)	679
Net income attributable to non-controlling interest		(7)	(8)
Net (loss) income attributable to Ultralife Corporation		(168)	671
Other comprehensive (loss) gain:
Foreign currency translation adjustments		(236)	103
Comprehensive (loss) income attributable to Ultralife Corporation		$ (404)	$ 774
Net (loss) income per share attributable to Ultralife common shareholders – basic (in dollars per share)		$ (1)	$ 4
Net (loss) income per share attributable to Ultralife common shareholders – diluted (in dollars per share)		$ (1)	$ 4
Weighted average shares outstanding – basic (in shares)		16,104	15,973
Potential common shares (in shares)		0	179
Weighted average shares outstanding - diluted (in shares)		16,104	16,152

[1] Sales classified to U.S. include shipments to U.S.-based prime contractors which in some cases may serve non-U.S. projects.